Actinium Pharma Presents Survival Data from Extended Follow-

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Related Keywords

Astellas Pharma , Sandesh Seth , Matthew Beck , Prnewswire Actinium Pharmaceuticals Inc , Oncology Lg Chem Life Sciences , Actinium Pharmaceuticals Inc , Actimaba Program Expansion , Investor Relations Communications , Exchange Commission , Actimaba National Cancer Institute , Novartis , Society Of Hematologic Oncology , Hematologic Oncology , Study Results , Overall Survival , Deep Responses , Prolonged Survival , Adverse Risk Acute Myeloid Leukemia , Received Prior Venetoclax , Actinium Chairman , Program Expansion , Antileukemic Activity , Preclinical Model , National Cancer Institute , Life Sciences , Actinium Pharmaceuticals , Nc ,